Global Cardiac Implants Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. The cardiac implants market is being driven by the rise in the incidence of cardiovascular diseases and the growing geriatric population. A report from the American Heart Association revealed that in 2020, there were an estimated 244.1 million cases of ischemic heart disease (IHD) globally, with a higher prevalence in males compared to females. Additionally, the Centers for Disease Control and Prevention reported that in 2020, approximately 20.1 million adults aged 20 and older in the United States had coronary heart disease (CAD), making it the most common type of heart disease in the country. Factors such as diabetes, overweight or obesity, an unhealthy diet, physical inactivity, and excessive alcohol use contribute to the occurrence of heart disease. As the frequency of cardiovascular illnesses continues to rise worldwide, individuals affected by these conditions are increasingly opting for surgical procedures, including the use of cardiac implants, which is driving the market growth.
The growing acceptance of cardiac implants can be attributed to their effectiveness in treating cardiovascular diseases and improving patients’ quality of life. These implants help in managing abnormal heart rhythms, heart failure, and other cardiac conditions, providing necessary support and functionality to the heart. As a result, the cardiac implants market is expected to witness significant growth in the coming years. However, it is important to note that certain factors may restrain the market’s growth. The high cost of cardiac implants can be a barrier to access for some patients, limiting their adoption. Additionally, there may be potential side effects and complications associated with these implants, which can impact patient outcomes and deter some individuals from pursuing cardiac implant procedures. Despite these challenges, the rise in cardiovascular diseases and the increasing acceptance of cardiac implants indicate a growth trajectory for the market. Continued advancements in technology, ongoing research and development efforts, and improvements in healthcare infrastructure are expected to further drive market growth and enhance the effectiveness of cardiac implant procedures.
The key regions considered for the Global Cardiac Implants Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America holds a significant market share in the cardiac implants market, driven by various factors. The Centers for Disease Control and Prevention (CDC) reports an increase in the number of deaths due to heart diseases in the United States, with 659,041 reported in 2019 and 690,882 in 2020. The CDC identifies high blood pressure, diabetes, high LDL cholesterol, and smoking as key risk factors for heart disease and stroke. Furthermore, the CDC estimates that by 2030, approximately 12.1 million people in the United States will have atrial fibrillation. The growing prevalence of cardiovascular diseases in the region is expected to positively impact the usage of cardiac implants and drive market growth.
The introduction of new products and approvals by key market players further contributes to the growth of the cardiac implants market in North America. For example, Abbott received expanded indication approval from the United States Food and Drug Administration (FDA) for the CardioMEMS HF System in February 2022. This system, consisting of a small sensor implanted in a patient’s pulmonary artery, aids in the care of individuals with heart failure. Additionally, in April 2022, Abbott obtained FDA approval for the Aveir single-chamber (VR) leadless pacemaker, which treats patients with slow heart rhythms. These advancements and product launches enhance the treatment options available and drive market growth in the region.
Major market player included in this report are:
Boston Scientific Corporation
Stryker (Physio-Control Inc.)
Asahi Kasei Corporation (ZOLL Medical Corporation)
Koninklijke Philips N.V.
Recent Developments in the Market:
Ø In April 2022, Impulse Dynamics gained approval and introduced the Optimizer Smart Mini in the United States. The Optimizer Smart Mini is an Implantable Pulse Generator (IPG) and a Class III medical device designed to address moderate to severe heart failure.
Ø In July 2021, Angel Medical Systems, Inc. launched its flagship product, the Guardian device. The Guardian System is the first implantable cardiac detection monitor and patient-warning system specifically indicated for acute coronary syndrome (ACS) events, including silent heart attacks.
Global Cardiac Implants Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Product, Application, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Device type:
Implantable Cardioverter-defibrillators (ICDs)
Implantable Heart Rhythm Monitors
Implantable Hemodynamic Monitors
Acute Myocardial Infarction
Middle East & Africa
Rest of Middle East & Africa